Anhui Anke Biotechnology (Group)（300009）株式概要安徽安科生物技術（集団）有限公司 詳細300009 ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長1/6過去の実績2/6財務の健全性6/6配当金5/6報酬当社が推定した公正価値より0%で取引されている 収益は年間11.51%増加すると予測されています 同業他社や業界と比較して、良好な取引価格 リスク分析不安定な配当実績 すべてのリスクチェックを見る300009 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW476,166 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA476,166 investors already sharing narrativesYour Fair ValueCN¥Current PriceCN¥8.2012.8% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture04b2016201920222025202620282031Revenue CN¥4.1bEarnings CN¥1.1bAdvancedSet Fair ValueView all narrativesAnhui Anke Biotechnology (Group) Co., Ltd. 競合他社Shenzhen Kangtai Biological ProductsSymbol: SZSE:300601Market cap: CN¥13.7bJinyu Bio-technologySymbol: SHSE:600201Market cap: CN¥14.3bYili Chuanning BiotechnologyLtdSymbol: SZSE:301301Market cap: CN¥19.6bPacific Shuanglin Bio-pharmacySymbol: SZSE:000403Market cap: CN¥10.0b価格と性能株価の高値、安値、推移の概要Anhui Anke Biotechnology (Group)過去の株価現在の株価CN¥8.5552週高値CN¥13.0652週安値CN¥7.35ベータ0.361ヶ月の変化4.78%3ヶ月変化-3.50%1年変化-23.25%3年間の変化-11.95%5年間の変化-35.96%IPOからの変化3.65%最新ニュースお知らせ • Jul 01Anhui Anke Biotechnology (Group) Co., Ltd. to Report First Half, 2026 Results on Aug 26, 2026Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report first half, 2026 results on Aug 26, 2026Declared Dividend • May 27Dividend of CN¥0.25 announcedShareholders will receive a dividend of CN¥0.25. Ex-date: 29th May 2026 Payment date: 29th May 2026 Dividend yield will be 3.0%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (60% earnings payout ratio) and cash flows (61% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 11% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 8 non-independent directors. Independent Director Lu Shi Yao was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Mar 31+ 1 more updateAnhui Anke Biotechnology (Group) Co., Ltd. to Report Q1, 2026 Results on Apr 24, 2026Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026お知らせ • Dec 31Anhui Anke Biotechnology (Group) Co., Ltd. to Report Fiscal Year 2025 Results on Mar 31, 2026Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report fiscal year 2025 results on Mar 31, 2026お知らせ • Sep 30Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025最新情報をもっと見るRecent updatesお知らせ • Jul 01Anhui Anke Biotechnology (Group) Co., Ltd. to Report First Half, 2026 Results on Aug 26, 2026Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report first half, 2026 results on Aug 26, 2026Declared Dividend • May 27Dividend of CN¥0.25 announcedShareholders will receive a dividend of CN¥0.25. Ex-date: 29th May 2026 Payment date: 29th May 2026 Dividend yield will be 3.0%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (60% earnings payout ratio) and cash flows (61% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 11% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 8 non-independent directors. Independent Director Lu Shi Yao was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Mar 31+ 1 more updateAnhui Anke Biotechnology (Group) Co., Ltd. to Report Q1, 2026 Results on Apr 24, 2026Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026お知らせ • Dec 31Anhui Anke Biotechnology (Group) Co., Ltd. to Report Fiscal Year 2025 Results on Mar 31, 2026Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report fiscal year 2025 results on Mar 31, 2026お知らせ • Sep 30Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025お知らせ • Jul 02Anhui Anke Biotechnology (Group) Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025お知らせ • Apr 23Anhui Anke Biotechnology (Group) Co., Ltd. Approves Profit Distribution for 2024Anhui Anke Biotechnology (Group) Co., Ltd. at its Annual General Meeting of 2024 held on 18 April 2025, approved 2024 profit distribution plan with Cash dividend/10 shares (tax included): CNY 1.50000000.お知らせ • Mar 31Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025お知らせ • Mar 30Anhui Anke Biotechnology (Group) Co., Ltd. Proposes Final Cash Dividend for the Year 2024Anhui Anke Biotechnology (Group) Co., Ltd. announced on 28 March 2025 the profit distribution proposal for 2024 as follows: Final Cash dividend per 10 shares (tax included) of CNY 1.50000000.お知らせ • Mar 28Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 18, 2025Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 18, 2025, at 09:30 China Standard Time. Location: The Company's Meeting Room, Hefei, Anhui Chinaお知らせ • Jan 09Anhui Anke Biotechnology (Group) Co., Ltd. Approves Cash Dividend for Third Quarter of 2024Anhui Anke Biotechnology (Group) Co., Ltd. in its Extraordinary General Meeting of 2025 on 7 January 2025 approved Cash dividend/10 shares (tax included) of CNY 1.00000000 for third quarter of 2024.お知らせ • Dec 31Anhui Anke Biotechnology (Group) Co., Ltd. to Report Fiscal Year 2024 Results on Mar 28, 2025Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report fiscal year 2024 results on Mar 28, 2025お知らせ • Dec 21Anhui Anke Biotechnology (Group) Co., Ltd. Proposes Dividend for the Third Quarter of 2024Anhui Anke Biotechnology (Group) Co., Ltd. announced on 20 December 2024 the profit distribution proposal for the third quarter of 2024 as follows: Cash dividend/10 shares (tax included): CNY 1.0.Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.15 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.10 (down from CN¥0.15 in 3Q 2023). Revenue: CN¥622.5m (down 15% from 3Q 2023). Net income: CN¥173.6m (down 33% from 3Q 2023). Profit margin: 28% (down from 35% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥8.99, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 25x in the Biotechs industry in China. Total loss to shareholders of 24% over the past three years.お知らせ • Sep 30Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024Valuation Update With 7 Day Price Move • Sep 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥8.73, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 21x in the Biotechs industry in China. Total loss to shareholders of 21% over the past three years.Reported Earnings • Aug 28Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.12 (down from CN¥0.13 in 2Q 2023). Revenue: CN¥642.7m (down 7.3% from 2Q 2023). Net income: CN¥198.4m (down 5.9% from 2Q 2023). Profit margin: 31% (in line with 2Q 2023). Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.お知らせ • Jun 29Anhui Anke Biotechnology (Group) Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024Declared Dividend • May 23Dividend of CN¥0.25 announcedDividend of CN¥0.25 is the same as last year. Ex-date: 27th May 2024 Payment date: 27th May 2024 Dividend yield will be 2.5%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (47% earnings payout ratio) and cash flows (59% cash payout ratio). The dividend has increased by an average of 22% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 16% over the next year, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.11 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.13 (up from CN¥0.11 in 1Q 2023). Revenue: CN¥656.1m (up 10% from 1Q 2023). Net income: CN¥217.7m (up 17% from 1Q 2023). Profit margin: 33% (up from 31% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.お知らせ • Mar 30Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024お知らせ • Mar 28Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 18, 2024Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 18, 2024, at 09:30 China Standard Time. Location: The Company's Meeting Room, Hefei, Anhui ChinaReported Earnings • Mar 28Full year 2023 earnings released: EPS: CN¥0.51 (vs CN¥0.43 in FY 2022)Full year 2023 results: EPS: CN¥0.51 (up from CN¥0.43 in FY 2022). Revenue: CN¥2.87b (up 23% from FY 2022). Net income: CN¥847.2m (up 21% from FY 2022). Profit margin: 30% (in line with FY 2022). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CN¥9.84, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 20% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.03 per share.お知らせ • Dec 29Anhui Anke Biotechnology (Group) Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report fiscal year 2023 results on Mar 28, 2024Board Change • Oct 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 8 non-independent directors. Independent Director Feihu Chen was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 25Third quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.15 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.15 (up from CN¥0.15 in 3Q 2022). Revenue: CN¥734.1m (up 17% from 3Q 2022). Net income: CN¥258.1m (up 3.3% from 3Q 2022). Profit margin: 35% (down from 40% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.お知らせ • Sep 30Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q3, 2023 Results on Oct 25, 2023Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q3, 2023 results on Oct 25, 2023Reported Earnings • Aug 24Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.10 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.13 (up from CN¥0.10 in 2Q 2022). Revenue: CN¥693.1m (up 27% from 2Q 2022). Net income: CN¥210.7m (up 23% from 2Q 2022). Profit margin: 30% (in line with 2Q 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 29Full year 2022 earnings released: EPS: CN¥0.43 (vs CN¥0.13 in FY 2021)Full year 2022 results: EPS: CN¥0.43 (up from CN¥0.13 in FY 2021). Revenue: CN¥2.33b (up 7.5% from FY 2021). Net income: CN¥703.3m (up 240% from FY 2021). Profit margin: 30% (up from 9.5% in FY 2021). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Dec 13Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥11.39, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 30x in the Biotechs industry in China. Total returns to shareholders of 22% over the past three years.Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 8 non-independent directors. Non-Independent Director Zhen Xu was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.11 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.15 (up from CN¥0.11 in 3Q 2021). Revenue: CN¥626.0m (up 8.3% from 3Q 2021). Net income: CN¥249.8m (up 35% from 3Q 2021). Profit margin: 40% (up from 32% in 3Q 2021). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Reported Earnings • Aug 26Second quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.075 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.10 (up from CN¥0.075 in 2Q 2021). Revenue: CN¥547.4m (up 13% from 2Q 2021). Net income: CN¥171.5m (up 45% from 2Q 2021). Profit margin: 31% (up from 24% in 2Q 2021). Over the next year, revenue is forecast to grow 32%, compared to a 33% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 29First quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.075 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.11 (up from CN¥0.075 in 1Q 2021). Revenue: CN¥533.4m (up 10.0% from 1Q 2021). Net income: CN¥172.9m (up 38% from 1Q 2021). Profit margin: 32% (up from 26% in 1Q 2021). Over the next year, revenue is forecast to grow 28%, compared to a 47% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 8 non-independent directors. Non-Independent Director Zhen Xu was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Reported Earnings • Apr 03Full year 2021 earnings released: EPS: CN¥0.13 (vs CN¥0.22 in FY 2020)Full year 2021 results: EPS: CN¥0.13 (down from CN¥0.22 in FY 2020). Revenue: CN¥2.17b (up 28% from FY 2020). Net income: CN¥206.6m (down 42% from FY 2020). Profit margin: 9.5% (down from 21% in FY 2020). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Jan 21Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to CN¥11.27, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 34x in the Biotechs industry in China. Total returns to shareholders of 38% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥18.44 per share.Reported Earnings • Oct 31Third quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.084 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥578.2m (up 31% from 3Q 2020). Net income: CN¥185.4m (up 36% from 3Q 2020). Profit margin: 32% (up from 31% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 22Second quarter 2021 earnings released: EPS CN¥0.075 (vs CN¥0.049 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥484.4m (up 22% from 2Q 2020). Net income: CN¥118.4m (up 46% from 2Q 2020). Profit margin: 24% (up from 20% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 9% per year.Valuation Update With 7 Day Price Move • May 24Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to CN¥15.00, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 47x in the Biotechs industry in China. Total returns to shareholders of 27% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥22.34 per share.Reported Earnings • Apr 30First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.062 in 1Q 2020)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: CN¥484.8m (up 54% from 1Q 2020). Net income: CN¥125.6m (up 54% from 1Q 2020). Profit margin: 26% (in line with 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.Reported Earnings • Apr 08Full year 2020 earnings released: EPS CN¥0.26 (vs CN¥0.092 in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: CN¥1.70b (flat on FY 2019). Net income: CN¥359.0m (up 188% from FY 2019). Profit margin: 21% (up from 7.3% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Feb 06New 90-day low: CN¥13.69The company is down 17% from its price of CN¥16.55 on 06 November 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.91 per share.Is New 90 Day High Low • Dec 28New 90-day low: CN¥14.64The company is down 10.0% from its price of CN¥16.21 on 30 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.83 per share.Is New 90 Day High Low • Dec 12New 90-day low: CN¥14.71The company is down 7.0% from its price of CN¥15.90 on 11 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.87 per share.Is New 90 Day High Low • Nov 25New 90-day low: CN¥15.69The company is down 8.0% from its price of CN¥17.10 on 27 August 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.43 per share.Reported Earnings • Oct 29Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥166.6m, down 42% from the prior year. Total revenue was CN¥1.70b over the last 12 months, up 5.9% from the prior year.株主還元300009CN BiotechsCN 市場7D3.5%6.5%5.1%1Y-23.2%-22.2%12.8%株主還元を見る業界別リターン: 300009過去 1 年間で-22.2 % の収益を上げたCN Biotechs業界を上回りました。リターン対市場: 300009は、過去 1 年間で12.8 % のリターンを上げたCN市場を下回りました。価格変動Is 300009's price volatile compared to industry and market?300009 volatility300009 Average Weekly Movement4.7%Biotechs Industry Average Movement7.1%Market Average Movement7.4%10% most volatile stocks in CN Market12.6%10% least volatile stocks in CN Market4.4%安定した株価: 300009 、 CN市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 300009の 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト20002,505n/awww.ankebio.com安徽安科生物技術（集団）有限公司は、中国国内および国際的に医薬品の開発、製造、販売を行っている。同社は、「アンソモン」の名称で注射用ヒト成長ホルモン、「アンテルフェロン」の名称で注射用遺伝子組換えヒトインターフェロンα2b凍結乾燥粉末、液体、プレフィルドシリンジ、遺伝子組換えヒトインターフェロンα2bクリーム、点眼薬、座薬を提供している。抗精子抗体、精液白血球ペルオキシダーゼ染色、精液1回処理、精子低浸透圧染色、精子寿命検出、精子染色検出、精子アクロシン検出、精子DNA断片化染色、レプチンおよび免疫組織化学診断キットを提供している。さらに、絆創膏、内服液、外用剤、軟膏、ペプチド原薬、アンチエイジング、マスク、エッセンシャルリキッドなどのビューティーケア製品、マウスウォッシュ、経口粉末剤、滴下剤、錠剤、カプセル剤などの合成医薬品も提供している。さらに、常染色体、性染色体、常染色体と性染色体の組み合わせ、その他のキット、父子関係検査セットパッケージ、腫瘍生物学的免疫療法製品、DNA検査プロフェッショナルサービスを提供している。さらに、同社はANTRASTUINブランドで乳がんや胃がんの患者を治療するためのトラスツズマブ、非小細胞肺がんの治療のためのベバシズマブ、進行がんのための抗PD1などのモノクローナル抗体医薬品を提供している。同社は2000年に設立され、中国の合肥市に本社を置いている。もっと見るAnhui Anke Biotechnology (Group) Co., Ltd. 基礎のまとめAnhui Anke Biotechnology (Group) の収益と売上を時価総額と比較するとどうか。300009 基礎統計学時価総額CN¥14.25b収益（TTM）CN¥693.78m売上高(TTM)CN¥2.56b20.5xPER（株価収益率5.6xP/Sレシオ300009 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計300009 損益計算書（TTM）収益CN¥2.56b売上原価CN¥647.97m売上総利益CN¥1.91bその他の費用CN¥1.22b収益CN¥693.78m直近の収益報告Mar 31, 2026次回決算日Aug 26, 2026一株当たり利益（EPS）0.42グロス・マージン74.68%純利益率27.11%有利子負債／自己資本比率0%300009 の長期的なパフォーマンスは？過去の実績と比較を見る配当金2.9%現在の配当利回り60%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/07 14:17終値2026/08/07 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Anhui Anke Biotechnology (Group) Co., Ltd. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Chao LiCitic Securities Co., Ltd.Xiao Wei LinEverbright Securities Co. Ltd.Changyan XieGuosen Securities Co., Ltd.4 その他のアナリストを表示
お知らせ • Jul 01Anhui Anke Biotechnology (Group) Co., Ltd. to Report First Half, 2026 Results on Aug 26, 2026Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report first half, 2026 results on Aug 26, 2026
Declared Dividend • May 27Dividend of CN¥0.25 announcedShareholders will receive a dividend of CN¥0.25. Ex-date: 29th May 2026 Payment date: 29th May 2026 Dividend yield will be 3.0%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (60% earnings payout ratio) and cash flows (61% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 11% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 8 non-independent directors. Independent Director Lu Shi Yao was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 31+ 1 more updateAnhui Anke Biotechnology (Group) Co., Ltd. to Report Q1, 2026 Results on Apr 24, 2026Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026
お知らせ • Dec 31Anhui Anke Biotechnology (Group) Co., Ltd. to Report Fiscal Year 2025 Results on Mar 31, 2026Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report fiscal year 2025 results on Mar 31, 2026
お知らせ • Sep 30Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025
お知らせ • Jul 01Anhui Anke Biotechnology (Group) Co., Ltd. to Report First Half, 2026 Results on Aug 26, 2026Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report first half, 2026 results on Aug 26, 2026
Declared Dividend • May 27Dividend of CN¥0.25 announcedShareholders will receive a dividend of CN¥0.25. Ex-date: 29th May 2026 Payment date: 29th May 2026 Dividend yield will be 3.0%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (60% earnings payout ratio) and cash flows (61% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 11% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 8 non-independent directors. Independent Director Lu Shi Yao was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 31+ 1 more updateAnhui Anke Biotechnology (Group) Co., Ltd. to Report Q1, 2026 Results on Apr 24, 2026Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026
お知らせ • Dec 31Anhui Anke Biotechnology (Group) Co., Ltd. to Report Fiscal Year 2025 Results on Mar 31, 2026Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report fiscal year 2025 results on Mar 31, 2026
お知らせ • Sep 30Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025
お知らせ • Jul 02Anhui Anke Biotechnology (Group) Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025
お知らせ • Apr 23Anhui Anke Biotechnology (Group) Co., Ltd. Approves Profit Distribution for 2024Anhui Anke Biotechnology (Group) Co., Ltd. at its Annual General Meeting of 2024 held on 18 April 2025, approved 2024 profit distribution plan with Cash dividend/10 shares (tax included): CNY 1.50000000.
お知らせ • Mar 31Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025
お知らせ • Mar 30Anhui Anke Biotechnology (Group) Co., Ltd. Proposes Final Cash Dividend for the Year 2024Anhui Anke Biotechnology (Group) Co., Ltd. announced on 28 March 2025 the profit distribution proposal for 2024 as follows: Final Cash dividend per 10 shares (tax included) of CNY 1.50000000.
お知らせ • Mar 28Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 18, 2025Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 18, 2025, at 09:30 China Standard Time. Location: The Company's Meeting Room, Hefei, Anhui China
お知らせ • Jan 09Anhui Anke Biotechnology (Group) Co., Ltd. Approves Cash Dividend for Third Quarter of 2024Anhui Anke Biotechnology (Group) Co., Ltd. in its Extraordinary General Meeting of 2025 on 7 January 2025 approved Cash dividend/10 shares (tax included) of CNY 1.00000000 for third quarter of 2024.
お知らせ • Dec 31Anhui Anke Biotechnology (Group) Co., Ltd. to Report Fiscal Year 2024 Results on Mar 28, 2025Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report fiscal year 2024 results on Mar 28, 2025
お知らせ • Dec 21Anhui Anke Biotechnology (Group) Co., Ltd. Proposes Dividend for the Third Quarter of 2024Anhui Anke Biotechnology (Group) Co., Ltd. announced on 20 December 2024 the profit distribution proposal for the third quarter of 2024 as follows: Cash dividend/10 shares (tax included): CNY 1.0.
Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.15 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.10 (down from CN¥0.15 in 3Q 2023). Revenue: CN¥622.5m (down 15% from 3Q 2023). Net income: CN¥173.6m (down 33% from 3Q 2023). Profit margin: 28% (down from 35% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥8.99, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 25x in the Biotechs industry in China. Total loss to shareholders of 24% over the past three years.
お知らせ • Sep 30Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024
Valuation Update With 7 Day Price Move • Sep 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥8.73, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 21x in the Biotechs industry in China. Total loss to shareholders of 21% over the past three years.
Reported Earnings • Aug 28Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.12 (down from CN¥0.13 in 2Q 2023). Revenue: CN¥642.7m (down 7.3% from 2Q 2023). Net income: CN¥198.4m (down 5.9% from 2Q 2023). Profit margin: 31% (in line with 2Q 2023). Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
お知らせ • Jun 29Anhui Anke Biotechnology (Group) Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024
Declared Dividend • May 23Dividend of CN¥0.25 announcedDividend of CN¥0.25 is the same as last year. Ex-date: 27th May 2024 Payment date: 27th May 2024 Dividend yield will be 2.5%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (47% earnings payout ratio) and cash flows (59% cash payout ratio). The dividend has increased by an average of 22% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 16% over the next year, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.11 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.13 (up from CN¥0.11 in 1Q 2023). Revenue: CN¥656.1m (up 10% from 1Q 2023). Net income: CN¥217.7m (up 17% from 1Q 2023). Profit margin: 33% (up from 31% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
お知らせ • Mar 30Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024
お知らせ • Mar 28Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 18, 2024Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 18, 2024, at 09:30 China Standard Time. Location: The Company's Meeting Room, Hefei, Anhui China
Reported Earnings • Mar 28Full year 2023 earnings released: EPS: CN¥0.51 (vs CN¥0.43 in FY 2022)Full year 2023 results: EPS: CN¥0.51 (up from CN¥0.43 in FY 2022). Revenue: CN¥2.87b (up 23% from FY 2022). Net income: CN¥847.2m (up 21% from FY 2022). Profit margin: 30% (in line with FY 2022). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CN¥9.84, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 20% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.03 per share.
お知らせ • Dec 29Anhui Anke Biotechnology (Group) Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report fiscal year 2023 results on Mar 28, 2024
Board Change • Oct 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 8 non-independent directors. Independent Director Feihu Chen was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 25Third quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.15 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.15 (up from CN¥0.15 in 3Q 2022). Revenue: CN¥734.1m (up 17% from 3Q 2022). Net income: CN¥258.1m (up 3.3% from 3Q 2022). Profit margin: 35% (down from 40% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
お知らせ • Sep 30Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q3, 2023 Results on Oct 25, 2023Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q3, 2023 results on Oct 25, 2023
Reported Earnings • Aug 24Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.10 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.13 (up from CN¥0.10 in 2Q 2022). Revenue: CN¥693.1m (up 27% from 2Q 2022). Net income: CN¥210.7m (up 23% from 2Q 2022). Profit margin: 30% (in line with 2Q 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 29Full year 2022 earnings released: EPS: CN¥0.43 (vs CN¥0.13 in FY 2021)Full year 2022 results: EPS: CN¥0.43 (up from CN¥0.13 in FY 2021). Revenue: CN¥2.33b (up 7.5% from FY 2021). Net income: CN¥703.3m (up 240% from FY 2021). Profit margin: 30% (up from 9.5% in FY 2021). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Dec 13Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥11.39, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 30x in the Biotechs industry in China. Total returns to shareholders of 22% over the past three years.
Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 8 non-independent directors. Non-Independent Director Zhen Xu was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.11 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.15 (up from CN¥0.11 in 3Q 2021). Revenue: CN¥626.0m (up 8.3% from 3Q 2021). Net income: CN¥249.8m (up 35% from 3Q 2021). Profit margin: 40% (up from 32% in 3Q 2021). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Reported Earnings • Aug 26Second quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.075 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.10 (up from CN¥0.075 in 2Q 2021). Revenue: CN¥547.4m (up 13% from 2Q 2021). Net income: CN¥171.5m (up 45% from 2Q 2021). Profit margin: 31% (up from 24% in 2Q 2021). Over the next year, revenue is forecast to grow 32%, compared to a 33% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 29First quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.075 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.11 (up from CN¥0.075 in 1Q 2021). Revenue: CN¥533.4m (up 10.0% from 1Q 2021). Net income: CN¥172.9m (up 38% from 1Q 2021). Profit margin: 32% (up from 26% in 1Q 2021). Over the next year, revenue is forecast to grow 28%, compared to a 47% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 8 non-independent directors. Non-Independent Director Zhen Xu was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Reported Earnings • Apr 03Full year 2021 earnings released: EPS: CN¥0.13 (vs CN¥0.22 in FY 2020)Full year 2021 results: EPS: CN¥0.13 (down from CN¥0.22 in FY 2020). Revenue: CN¥2.17b (up 28% from FY 2020). Net income: CN¥206.6m (down 42% from FY 2020). Profit margin: 9.5% (down from 21% in FY 2020). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Jan 21Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to CN¥11.27, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 34x in the Biotechs industry in China. Total returns to shareholders of 38% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥18.44 per share.
Reported Earnings • Oct 31Third quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.084 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥578.2m (up 31% from 3Q 2020). Net income: CN¥185.4m (up 36% from 3Q 2020). Profit margin: 32% (up from 31% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 22Second quarter 2021 earnings released: EPS CN¥0.075 (vs CN¥0.049 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥484.4m (up 22% from 2Q 2020). Net income: CN¥118.4m (up 46% from 2Q 2020). Profit margin: 24% (up from 20% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 9% per year.
Valuation Update With 7 Day Price Move • May 24Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to CN¥15.00, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 47x in the Biotechs industry in China. Total returns to shareholders of 27% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥22.34 per share.
Reported Earnings • Apr 30First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.062 in 1Q 2020)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: CN¥484.8m (up 54% from 1Q 2020). Net income: CN¥125.6m (up 54% from 1Q 2020). Profit margin: 26% (in line with 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.
Reported Earnings • Apr 08Full year 2020 earnings released: EPS CN¥0.26 (vs CN¥0.092 in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: CN¥1.70b (flat on FY 2019). Net income: CN¥359.0m (up 188% from FY 2019). Profit margin: 21% (up from 7.3% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Feb 06New 90-day low: CN¥13.69The company is down 17% from its price of CN¥16.55 on 06 November 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.91 per share.
Is New 90 Day High Low • Dec 28New 90-day low: CN¥14.64The company is down 10.0% from its price of CN¥16.21 on 30 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.83 per share.
Is New 90 Day High Low • Dec 12New 90-day low: CN¥14.71The company is down 7.0% from its price of CN¥15.90 on 11 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.87 per share.
Is New 90 Day High Low • Nov 25New 90-day low: CN¥15.69The company is down 8.0% from its price of CN¥17.10 on 27 August 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.43 per share.
Reported Earnings • Oct 29Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥166.6m, down 42% from the prior year. Total revenue was CN¥1.70b over the last 12 months, up 5.9% from the prior year.
